Testosterone-like treatment plus radium for bone-spread prostate cancer
Part of Cancer clinical trials.
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy or surgery, and it is mostly adenocarcinoma
- Your cancer has spread to the bone (seen on a bone scan within 2 months)
- Your testosterone level is in the “low castration” range (≤ 50 ng/dL) and your cancer is still progressing
- Your PSA blood test is at least 2.0 ng/mL
- You are taking bone-protecting medicine (zoledronic acid or denosumab) for at least 4 weeks and will continue it
- Your body can handle treatment (ECOG 0–1) and you are not using opioid pain meds (strong opioid pain meds are not allowed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
This trial tests a drug called radium-223 for prostate cancer that has spread to the bonescars. It's for people who have already had a standard combination treatment and need another option. The goal is to see if adding radium-223 can help control the disease.
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.